SK Biopharmaceuticals and Eurofarma Form Joint Venture for AI Epilepsy Platform

October 29, 2025
SK Biopharmaceuticals and Eurofarma have launched Mentis Care, a joint venture based in Toronto, to develop an AI-driven epilepsy management platform combining real-time seizure detection and predictive analytics.

SK Biopharmaceuticals and Eurofarma have established a joint venture named Mentis Care to develop an AI-based platform for epilepsy management, announced in a press release. The venture aims to commercialize an integrated digital ecosystem that combines real-time seizure detection, prediction algorithms, and clinical decision support tools.

Mentis Care is headquartered in the MaRS Discovery District in Toronto, one of North America's major innovation hubs. It will focus on advancing AI-driven electroencephalography and wearable technologies developed by SK Biopharmaceuticals since 2018. The company plans to expand its team, pursue clinical validation of its algorithms, and strengthen collaborations with academic and industry partners.

Eurofarma will lead business strategy and AI data learning efforts for the joint venture, building on its existing partnership with SK Biopharmaceuticals, which began in 2022 for the Latin American commercialization of the anti-seizure medication cenobamate. Hassan Kotob, former CEO of Brain Scientific, has been appointed as CEO of Mentis Care to oversee the platform’s development and operations.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

11/07
Anthill Unveils Anthill Cloud for AI-Driven Pharma Marketing
11/07
ACTO Launches ACTOverse Marketplace for Life Sciences Partners
11/06
Geeks360 Launches AI Platform to Integrate Marketing and Operations for Healthcare Firms
11/06
Fosun Highlights Global Innovation and AI Initiatives at Sustainability Leaders Conference
11/06
Healthcare Triangle Signs LOI to Acquire Teyame.AI for AI-Powered Patient Engagement

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation

ModelOp

The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.

Read more

You May Also Like